BioCentury
ARTICLE | Clinical News

FDA grants Regeneron's evinacumab breakthrough therapy designation for HoFH

May 12, 2017 5:39 AM UTC

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA granted breakthrough therapy designation to evinacumab (REGN1500) to treat homozygous familial hypercholesterolemia (HoFH). The mAb targeting ang...

BCIQ Company Profiles

Regeneron Pharmaceuticals Inc.

BCIQ Target Profiles

Angiopoietin-like 3 (ANGPTL3)